Loading...
http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.redefining-healthcaregk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-our-employeesgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-our-principalsgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-business-1gk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-businessgk-is-126.jpg http://obs.com.pk/modules/mod_image_show_gk4/cache/main-banners.we-care-about-your-healthgk-is-126.jpg

Scientific Events

Corporate Events

Trainings

Product Launches

CSR Events

Company News

A+ A A-

Januvia, December 2010

JANUVIA, the block buster brand of Merck & Co, is a brand leader of Sitagliptin was launched in Pakistan in December, 2010. Up to date more than 17 million patients have been prescribed JANUVIA to treat Type-2 Diabetes Mellitus.

The launch symposium for Januvia was held in Singapore on January 28, 2011. Pakistan’s best Endocrinologists like Prof. Abdul Jabbar from Aga Khan University Hospital, Dr. M. A. Ibrahim & 17 other prominent Endocrinologists, Diabetologist and Physicians attended the symposium. Dr. Tan Chee Eng, Consultant Endocrinologist at Gleneagles Medical Centre, Singapore delivered a very informative presentation on Update on Management of Type 2 Diabetes Mellitus. Dr. M. A. Ibrahim also gave a presentation on Diabetes in Pakistan. Director Medical Services of MSD Singapore also attended the session and delivered a very informative presentation.

Januvia’s physiological mode of action and remarkable safety parameters makes it the drug of first choice either alone or as an add-on with Metformin, Sulfonylurea, TZDs or Insulin for Type-2 Diabetes management.  

Copyrights © 2011-2014 All Rights Reserved OBS.